# CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

> **NCT06777979** · PHASE1 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent B Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **DEVICE:** CD19-CD22 CAR T cell infusion

## Key facts

- **NCT ID:** NCT06777979
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2030-01
- **Final completion:** 2031-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06777979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06777979, "CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06777979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*